Foundation Medicine

FDA announces approval of first breakthrough-designated test

Friday, December 8, 2017

The FDA approved the FoundationOne CDx (F1CDx), the first breakthrough-designated, next generation sequencing (NGS)-based in vitro diagnostic (IVD) test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. The Centers for Medicare & Medicaid Services (CMS) at the same time proposed coverage of the F1CDx. The test is the second IVD to be approved and covered after overlapping review by the FDA and CMS under the Parallel Review Program, which facilitates earlier access to innovative medical technologies for Medicare beneficiaries.

[Read More]

Foundation Medicine appoints Troy Cox CEO

Monday, January 9, 2017

Foundation Medicine has announced that, as part of the succession of its executive leadership, the board of directors has appointed Troy Cox, a highly regarded global biopharma leader, as chief executive officer to succeed Michael Pellini, M.D. Dr. Pellini, who has served as chief executive officer of the company since 2011, has been appointed chairman of the company’s board of directors. Alexis Borisy, founding chief executive officer and current chairman of the board for Foundation Medicine, will continue to serve on the board of directors. Cox will also join the board of directors. All of these changes will become effective by February 6, 2017.

[Read More]

Flatiron Health, Foundation Medicine oncology clinico-genomic database

Friday, November 4, 2016

Flatiron Health and Foundation Medicine have announced the launch of a clinico-genomic database designed to help researchers and biopharmaceutical partners accelerate the development of targeted therapeutics and immunotherapies to treat cancer. The clinico-genomic database, containing information on nearly 20,000 patients, is one of the largest and most comprehensive information efforts of its kind in oncology.

[Read More]

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

Monday, January 19, 2015

The quest for those patient populations that will benefit the most from spe­cific drugs and diagnostics has spurred Roche Holding, the world’s biggest seller of cancer drugs, to spend $1.03 billion for a majority stake in Foundation Medicine (FMI) to create a broad collaboration to advance the use of FMI’s genomic tests for solid tumors and blood cancers.

[Read More]

Roche to acquire majority ownership of Foundation Medicine

Monday, January 12, 2015

Foundation Medicine (FMI), based in Cambridge, Mass., and Roche will enter into a broad strategic collaboration to further advance Foundation Medicine’s position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients. Roche also will acquire majority ownership of Foundation Medicine.

[Read More]

Foundation Medicine, Flatiron Health collaborate to develop data platform

Wednesday, December 3, 2014

Foundation Medicine, a molecular information company based in Cambridge, Mass., and Flatiron Health, a healthcare technology company headquartered in New York, have announced a strategic collaboration to develop a unique, proprietary cloud-based information platform combining genomic and clinical treatment and outcomes data to significantly advance the field of precision medicine for cancer.

[Read More]